Free Trial
NASDAQ:COYA

Coya Therapeutics (COYA) Stock Price, News & Analysis

$8.15
+0.04 (+0.49%)
(As of 05/23/2024 ET)
Today's Range
$7.83
$8.55
50-Day Range
$7.99
$10.13
52-Week Range
$3.21
$10.69
Volume
71,575 shs
Average Volume
77,888 shs
Market Capitalization
$119.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00

Coya Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
71.8% Upside
$14.00 Price Target
Short Interest
Healthy
1.41% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.03mentions of Coya Therapeutics in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.87 out of 5 stars

Medical Sector

600th out of 915 stocks

Pharmaceutical Preparations Industry

269th out of 399 stocks

COYA stock logo

About Coya Therapeutics Stock (NASDAQ:COYA)

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.

COYA Stock Price History

COYA Stock News Headlines

Coya Therapeutics, Inc. (COYA)
See More Headlines
Receive COYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Coya Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/19/2024
Today
5/23/2024
Next Earnings (Estimated)
8/13/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:COYA
Fax
N/A
Employees
8
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$14.00
High Stock Price Target
$14.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+71.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-7,990,000.00
Pretax Margin
-156.31%

Debt

Sales & Book Value

Annual Sales
$6 million
Book Value
$2.22 per share

Miscellaneous

Free Float
12,864,000
Market Cap
$119.15 million
Optionable
Not Optionable
Beta
1.05
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. Howard Berman Ph.D. (Age 50)
    Chairman & CEO
    Comp: $833.75k
  • Dr. Fred Grossman D.O. (Age 62)
    FAPA, President & Chief Medical Officer
    Comp: $610.63k
  • Mr. David S. Snyder (Age 64)
    CFO & COO
    Comp: $610.94k
  • Dr. Gregory MacMichael Ph.D. (Age 68)
    Chief Technical Officer
  • Dr. Michelle Frazier Ph.D.
    Senior Vice President of Regulatory Affairs
  • Mr. Aaron Thome Ph.D.
    Head of Neuroinflammation Platform
  • Dr. Arun Swaminathan Ph.D.
    Chief Business Development Officer

COYA Stock Analysis - Frequently Asked Questions

Should I buy or sell Coya Therapeutics stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Coya Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" COYA shares.
View COYA analyst ratings
or view top-rated stocks.

What is Coya Therapeutics' stock price target for 2024?

1 Wall Street analysts have issued 12-month price targets for Coya Therapeutics' shares. Their COYA share price targets range from $14.00 to $14.00. On average, they anticipate the company's stock price to reach $14.00 in the next year. This suggests a possible upside of 71.8% from the stock's current price.
View analysts price targets for COYA
or view top-rated stocks among Wall Street analysts.

How have COYA shares performed in 2024?

Coya Therapeutics' stock was trading at $7.41 at the start of the year. Since then, COYA stock has increased by 10.0% and is now trading at $8.15.
View the best growth stocks for 2024 here
.

When is Coya Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our COYA earnings forecast
.

How were Coya Therapeutics' earnings last quarter?

Coya Therapeutics, Inc. (NASDAQ:COYA) announced its quarterly earnings results on Tuesday, March, 19th. The company reported $0.15 earnings per share for the quarter. The business had revenue of $6 million for the quarter.

When did Coya Therapeutics IPO?

Coya Therapeutics (COYA) raised $15 million in an IPO on Thursday, December 29th 2022. The company issued 3,050,000 shares at $5.00 per share.

Who are Coya Therapeutics' major shareholders?

Coya Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (5.80%).

How do I buy shares of Coya Therapeutics?

Shares of COYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:COYA) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners